Dr. Lynn Morris, head of HIV Virology at South Africa’s National Institute for Communicable Diseases and professor at the University of the Witwatersrand in Johannesburg, provided an overview of antibody research for HIV prevention. She laid out the current landscape; provided a glimpse of what is to come in this dynamic field; talked about where antibody work fits in the larger field of prevention research; and described how the Antibody Mediated Prevention (AMP) studies – ongoing proof-of-concept trials of the broadly neutralizing antibody VRC01 – might advance HIV prevention.

This was the fourth in our series of HIV Vaccine Awareness Day webinars. For details on the full series, visit avac.org/hvad.

Recording: YouTube / Audio / Slides

For more information, including the At-A-Glance and full program, click here.

Where:
Omni Shoreham Hotel
2500 Calvert Street NW
Washington, DC 20008

Lieutenant Colonel Julie Ake, Principal Deputy Director of the US Military HIV Research Program (MHRP), wraps up our HVAD webinar series by providing an overview of MHRP’s HIV program and helping to connect dots in the HIV vaccine field.

Ake takes us through the landmark RV144 trial, the first HIV vaccine trial to show efficacy, and gives a clear and compelling update on where HIV vaccine research is and where it needs to go to ensure the development of a safe and effective vaccine. She also provides insight into the linkages to HIV treatment and cure research, as well as other vaccine development efforts, illuminating in particular the ways in which HIV vaccine research has informed Ebola and Zika vaccine development.

This was the fifth in our series of HIV Vaccine Awareness Day webinars. For details on the full series, visit avac.org/hvad.

Recording: YouTube / Audio / Slides

Professor Linda-Gail Bekker is the Deputy Director of the Desmond Tutu HIV Centre, Chief Operating Officer at the Desmond Tutu HIV Foundation and Professor of Medicine at the University of Cape Town. She is also President-elect of the International AIDS Society.

Amongst many HIV prevention research activities that she leads, she is the principal investigator of the HVTN 100 vaccine trial, and in this webinar she discussed the latest in HIV vaccine research and the most recent updates on the plan to start a new vaccine efficacy trial later this year.

Listen / View Slides / Watch on YouTube / Watch Flash animation

John Mascola of the NIH Vaccine Research Center spoke about harnessing antibodies for HIV prevention and treatment. The recording includes a question and answer period with webinar participants.

For further background, click here to view his CROI plenary session. And this webinar is part of our post-CROI 2016 webinar series. Click to learn more.

Where: The New York Academy of Sciences Conference Center in Manhattan

Presented by: UNAIDS and the Microbiology & Infectious Diseases Discussion Group at the New York Academy of Sciences

Speakers:

• Steven G. Deeks, MD, University of California, San Francisc
• Peter Godfrey-Faussett, BA, MBBS, DTM&H, FRCP (UK), UNAID
• Maureen M. Goodenow, PhD, University of Florida Healt
• James Hakim, MBChB, FRCP, University of Zimbabw
• Mark Harrington, Treatment Action Grou
• Peter Lamptey, MD, DrPH, MPH, FHI36
• Linda Kupfer, PhD, Fogarty International Center, NI
• Luiz Loures, MD, MPH, UNAID
• Wafaa El Sadr, MD, MPH, Mailman School of Public Health, Columbia Universit
• Doug Webb, PhD, HIV, Health and Development Group, UNDP

On May 18, advocates around the world observed HIV Vaccine Awareness Day (HVAD)—an annual commemoration of the need for and commitment to the ongoing search for a vaccine. AVAC convened a webinar—Vaccines in Vivo: Advances in AIDS Vaccine Research—and updated a number of materials, including our “HVAD Toolkit” for those interested in easy-to-digest research updates.

This year brought the launch of long-awaited initiation of clinical trials building on positive results from the RV144 “Thai” trial. This effort is led by the Pox-Protein Public-Private Partnership (P5), including the the HIV Vaccine Trials Network, who joined the webinar to provide a status update of their current vaccine research and development program. We also featured Janssen, part of Johnson & Johnson, to provide an overview of the research program they are moving forward that focuses on a cross-clade vaccine product.

In this webinar we discussed:

• When and where the P5 trials are taking place?
• What questions will be asked in the P5 “licensure track” trials—designed to bring a product to market, and what will the “research” track address? [Click here for AVAC’s explanation of the dual tracks.]
• The pipeline beyond the P5 trials—including the candidate Janssen is developing
• The role for advocates in southern Africa and around the world in terms of keeping AIDS vaccine research on track

Join Project ACHIEVE, Ballroom Throwbacks, Impulse Group NYC, AVAC, and Columbia University Medical Center on Monday, May 18th for the 11th annual Vaccine-O-Licious – #VOL2015 with a special Q&A and Meet and Greet with the cast from Triangle Web Series.

Get your free tickets here

Vaccine-O-Licious is an annual event designed to spread the word about HIV Vaccine Awareness Day.The event brought together a variety of performers uniting through dance and song.Peppermint hosted this exciting evening of entertainment, with a little education too!

Address: Santos Party House, 96 Lafayette St, New York, NY, 10013

Doors Open: 6:30 PM

Special Q&A with the cast of Triangle Web Series at 7 PM

Show Time: 7:30 PM